Multi-million dollar drug partnership
CSL Agrees to $1.6 Billion Partnership for Experimental Kidney and Liver Drug
Anonymous
Key Points
1
CSL will fund Phase 2 and Phase 3 trials of lixudebart across the three targeted conditions.
2
Article 1 reports that clinical data so far showed improvements in kidney and liver function alongside a favourable safety profile.
3
Lixudebart was previously known as ALE.F02 and is described as a potential first-in-class therapy because it is designed to address inflammation and fibrosis simultaneously.
4
AAV-RPGN can cause kidney function to deteriorate rapidly—over days to weeks—and the article says many patients lose substantial or all kidney function despite immunosuppressive treatment.
5
The additional milestone payments are contingent on commercial success, rather than being paid upfront, limiting CSL’s near-term financial exposure beyond its initial payment.
CSL has struck a major deal to develop and sell an experimental kidney-liver drug, betting up to $1.6 billion on lixudebart from Swiss biotech Alentis Therapeutics. Pharmaceutical Technology reported that CSL will pay $355 million upfront to fund clinical trials for three rare conditions. If the drug succeeds commercially, Alentis could collect an additional $1.2 billion in milestone payments.
Lixudebart targets claudin-1, a protein involved in inflammation and fibrosis. The companies will split global profits 55-45 in CSL's favor if the drug reaches patients. Kalkine noted this represents CSL's largest rare-disease bet in recent years, expanding its footprint in hard-to-treat kidney and liver diseases.
Three Rare Diseases in the Crosshairs
CSL will fund Phase 2 and Phase 3 trials targeting three conditions: ANCA-associated vasculitis with rapidly progressive glomerulonephritis (AAV-RPGN), focal segmental glomerulosclerosis (FSGS), and primary sclerosing cholangitis (PSC). Pharmaceutical Technology explained that AAV-RPGN destroys kidney function in days or weeks. Many patients lose substantial kidney function despite heavy immunosuppressive treatment, leaving few options.
Lixudebart is designed as a potential first-in-class therapy because it tackles inflammation and fibrosis at the same time. Early clinical data showed improvements in kidney and liver function with a favorable safety profile, Kalkine reported. The drug was previously known as ALE.F02 before Alentis renamed it lixudebart.
How the Money Flows Between Partners
CSL's $355 million upfront payment covers drug development and trial costs. Alentis will earn up to $1.2 billion more if lixudebart hits commercial milestones—regulatory approval, patient enrollment goals, and sales targets. Kalkine noted this structure limits CSL's near-term financial risk because extra payments depend on the drug actually succeeding.
Once lixudebart reaches the market, CSL and Alentis will share profits globally. CSL gets 55% of profits while Alentis keeps 45%. This split reflects CSL's dominance in manufacturing and distribution while recognizing Alentis's role in discovering the original compound.
Why Kidney-Liver Diseases Matter to CSL
Rare kidney and liver diseases affect millions of patients worldwide but attract few drug makers. Many lack approved treatments or face limited options. Pharmaceutical Technology reported that CSL is betting lixudebart can fill this gap and become a blockbuster drug.
CSL's track record in immunology and rare diseases makes it an ideal partner. The company already operates in nephrology and hepatology. This deal marks the firm's latest push to build a stronger rare-disease franchise beyond its traditional blood-clotting and immune therapies.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
13
Articles
9
Reach
22
A
AnonymousAuthor
